- Vilanterol
-
- $10.00 / 1kg
-
2024-04-02
- CAS:503068-34-6
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 100 tons
- Vilanterol
-
- $10.00 / 1000g
-
2023-11-03
- CAS:503068-34-6
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 500tons
- Vilanterol
-
- $30.00 / 1kg
-
2023-09-15
- CAS:503068-34-6
- Min. Order: 1kg
- Purity: 99.9%
- Supply Ability: 20kg
|
| | Vilanterol Basic information |
| Product Name: | Vilanterol | | Synonyms: | Vilanterol;GW 642444X;Vilanterol API;GW 642444;GW642444;GW-642444;4-[(R)-2-[[6-[2-(2,6-Dichlorobenzyloxy)ethoxy]hexyl]amino]-1-hydroxyethyl]-2-hydroxymethylphenol;Vilanterol(GW642444) | | CAS: | 503068-34-6 | | MF: | C24H33Cl2NO5 | | MW: | 486.43 | | EINECS: | 690-631-3 | | Product Categories: | Inhibitors;Intermediate;503068-34-6 | | Mol File: | 503068-34-6.mol |  |
| | Vilanterol Chemical Properties |
| Boiling point | 646.7±55.0 °C(Predicted) | | density | 1?+-.0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | solution in ethanol | | pka | 9.99±0.20(Predicted) |
| | Vilanterol Usage And Synthesis |
| Definition | ChEBI: An dichlorobenzene derivative that is used in the form of its trifenate salt for treatment of chronic obstructive pulmonary disease. | | Biological Activity | vilanterol is a novel and selective agonist of β2-ar with a pec50 value of 10.37±0.05 [1].vilanterol is a novel long-acting β2-ar agonist (laba) with 24h activity in development for inhaled once daily treatment. in the radioligand binding studies, vilanterol has shown the binding affinity in the one-affinity site model with pkd values of 9.44±0.07 and 10.82±0.12 in the presence gpp(nh)p and absence gpp(nh)p, respectively. in dissociation studies, vilanterol has been reported to bind from the β2-ar with a dissociation t1/2 value of 3.5 min in the presence of gpp(nh)p. vilanterol has been found to have a good selectivity for β2-ar over the other β-ar receptor subtypes(β1and β3) with pec50 values of 10.37±0.05, 6.98±0.03 and 7.36±0.03, respectively. vilanterol has exhibited at least 1000-fold selectivity over both β1-and β3-ar subtypes [1]. | | references | [1] slack rj1, barrett vj, morrison vs, sturton rg, emmons aj, ford aj, knowles rg.in vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action.j pharmacol exp ther. 2013 jan; 344(1):218-30. |
| | Vilanterol Preparation Products And Raw materials |
|